Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Produced by URIT, it upgraded and optimized the AI deep learning recognition algorithm in 2019, has greatly improved the ability of rapid and intelligent analysis and identification of urine formed elements, which can meet the requirements of medical institutions for intelligence, automation, and rapid processing of large quantities of specimens.

AVRICORE HEALTH INC. (TSXV: AVCR) is pleased to announce that its wholly-owned subsidiary, HealthTab Ltd, has entered into a formal collaboration agreement with Abbott, a global healthcare company, to supply and distribute Abbott’s point-of-care testing products through the HealthTab™ platform in the UK.

The U.S. Food and Drug Administration announced today that it has cleared C2N Diagnostics' PrecivityAD2 blood test for use in adults as young as 40 who are experiencing signs of cognitive impairment, making it the first FDA-cleared Alzheimer's blood test available to patients this young. The clearance builds on nearly 20 years of ADDF investment in C2N's science and reflects the growing momentum of blood-based diagnostics in bringing earlier, more accurate detection into mainstream care and moving the field toward a new era of precision medicine.

Seegene Medical Foundation has signed an agreement with the Central Asian Biotechnology Association (CABA) and Open Healthcare to expand cooperation in diagnostic testing and health screening in Kazakhstan.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the second quarter ended June 30, 2026.

BGI Genomics recently announced that its NIFTY® Non‑invasive Prenatal Testing (NIPT) product has obtained the CE-IVDR Certificate from TÜV SÜD Product Service GmbH (a leading global Notified Body designated under the IVDR).

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed the sale of its microbiology business to Astorg, a leading pan-European private equity firm, for consideration of approximately $1.075 billion, consisting of cash and a $50 million seller note.

Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, today announced multiple U.S. Food and Drug Administration (FDA) 510(k) clearances that strengthen its connected clinical digital pathology portfolio, including the industry's first standalone, AI-assisted quality control software. These advancements are designed to help pathology laboratories deliver high-quality digital images more consistently and efficiently to support timely, confident diagnoses for patients at a critical moment when case volumes, staffing pressures, and diagnostic complexity continue to increase.

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the completion of Olink Explore HT proteomic analysis of approximately 5,500 research samples from The Michael J. Fox Foundation’s (MJFF) landmark study, the Parkinson’s Precision Medicine Initiative (PPMI). The resulting data are now in PPMI’s data repository, where they are available to the global research community.

Produced by Mindray, it can detect all routine physical and chemical items in urine and provide complete urine dry chemical analysis. The instrument has advantages of compact structure and simple operation.